Back
Singular Genomics
IPOOMIC.NASDAQPast

Singular Genomics

Biotech company focused on delivering genomic technologies

Company website ↗
Foundation year: 2016
IPO date
27/05/2021

About

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.


Number of employees

51 - 100


Headquarters

La Jolla, California, United States

Underwriters

F-Prime Capital, Domain Associates